Study Design
DesignRandomized, double-blind, placebo-controlled, active-controlled
Randomization4:2:1
BlindingDouble-blind
Enrollment567
Duration52 weeks
Treatment Arms
Bimekizumab 320mg 320mg SC q4w n=321
Ustekinumab 45/90mg 45mg or 90mg (weight-based) SC at Wk 0,4 then q12w n=163
Placebo → Bimekizumab Placebo Wk 0-16, then bimekizumab n=83
[{"id":"pasi90-w16","name":"PASI 90 at Week 16","type":"PRIMARY","unit":"%","results":[{"value":85,"arm_id":"bkzx-arm","p_value":0.001},{"value":49.7,"arm_id":"ust-arm"},{"value":4.8,"arm_id":"pbo-arm"}],"timepoint":"Week 16","description":"Near-complete clearance at 16 weeks vs ustekinumab and placebo."}]